See other companies on Welcome to the Jungle
Histowiz
Automated histopathology for researchers
- 21-100 employees
- Healthcare
- B2B
- Biology
- SaaS
- MedTech
- Prospect Lefferts Gardens, NY
Jump to section
Company mission
To fight cancer cooperatively instead of individually by connecting scientists and pathologists for online collaboration.
Our take
Biomedical researchers face a daunting hurdle in the form of disjointed and inaccessible visual databases housing tissue specimens. The fragmented nature of these data repositories hinders their progress, making it difficult to draw meaningful insights and conclusions from the wealth of information locked within.
In response to this pressing challenge, HistoWiz has embarked on a mission to bridge these gaps. Its approach involves the fusion of cutting-edge automated histology technology with the world's extensive preclinical pathology database. By doing so, the company not only simplifies and streamlines histopathology procedures but also ensures that researchers have access to a comprehensive, unified resource that facilitates their vital work.
This integration of data and technology holds the promise in accelerating breakthroughs in the biomedical field.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- 100% coverage on employee health, vision, and dental insurance, partial coverage for family
- Memberships to TeleDoc and TalkSpace (one year)
- Parental leave
- NY Commuter benefits
- Flexible Spending Accounts (FSA) and Health Savings Account (HSA)
- Retirement planning (401k)
- Onsite gym membership and commuter showers
- Team building events outside the office
Funding (last 2 of 6 rounds)
Oct 2021
$32m
SERIES A
Feb 2018
$2.8m
SEED
Total funding: $36.6m
This company has top investors
Leadership
Ke Cheng
(Founder)Received their Ph.D. in the laboratory of Pier Paolo Pandolfi at Harvard Medical School and led a team of investigators to publish papers in journals including Nature and Blood. Also worked as a Scientist at the Swiss Institute for Experimental Cancer Research.